Herborium Group Forecasts 7 Figures In Revenue & Royalties As "Lady Kama" Expects To Enter California

FORT LEE, N.J., Oct. 15, 2012 /PRNewswire/ -- Herborium Group, Inc., (HBRM) www.herborium.com, a Botanical Therapeutics® Company announced today that based on the results of the 3^rd Quarter, and estimated performance in the 4^th Quarter 2012, as well as rapid growth of sales and popularity of  Kamasutra™ spirit containing the Company's proprietary herbal formulation, the Company  expects estimated revenues in 2013 to reach 7 figures.

In the 4^th Quarter, Herborium will start receiving revenues from royalties for Kamasutra™ spirit sales that are already taking place across New Jersey and commence in New York before the end of October 2012.  In the first Quarter of 2013, "Lady Kama"  will debut in California.  New Jersey, New York and California together represent 18% of the total United States sale of liqueur.

Herborium sales of AcnEase®, it's proprietary all-botanical acne medicine that targets over 120 million acne sufferers in North America and Europe,  grew by over 21%  in the 3^rd Quarter of 2012 in comparison to the same Quarter of 2011.  Estimated sales for the 4^th Quarter continue to be even more optimistic as sales in September 2012 were the strongest ever in the history of the company.  AcnEase is being sold in the US and Canada as well as through European Union, and recently has also entered Australia and New Zealand.

"We are very pleased with the sales results of Herborium Team this year, and with marketing and sales progress of our Kamasutra™ partners. Our focus for the 4^th Quarter and for 2013 is to continue to lay the foundation for a strong recurring revenue base and profitability," said Dr. Agnes P. Olszewski, CEO and Chairwomen of Herborium Group.  

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals.  The Company uses clinical validation to establish and maintain a differential advantage.  The company sells its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: [email protected]

SOURCE Herborium Group, Inc.